Rabbit Recombinant Monoclonal PI3 Kinase p110 beta antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Rat, Mouse, Human samples. Cited in 103 publications.
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | ICC/IF | Flow Cyt (Intra) | IHC-P | |
---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended |
Mouse | Tested | Expected | Expected | Not recommended |
Rat | Tested | Expected | Expected | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/1000 | Notes For unpurified use at 1/1000 - 1/10000. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Mouse | Dilution info 1/1000 | Notes For unpurified use at 1/1000 - 1/10000. |
Species Human | Dilution info 1/1000 | Notes For unpurified use at 1/1000 - 1/10000. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/150 | Notes For unpurified use at 1/250 - 1/500. |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/20 | Notes For unpurified use at 1/100 - 1/1000. Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:15135396). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces. Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors. Has also a protein kinase activity showing autophosphorylation (PubMed:12502714).
PIK3C1, PIK3CB, PI3-kinase subunit beta, PI3K-beta, PI3Kbeta, PtdIns-3-kinase subunit beta, Serine/threonine protein kinase PIK3CB, PtdIns-3-kinase subunit p110-beta, p110beta
Rabbit Recombinant Monoclonal PI3 Kinase p110 beta antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Rat, Mouse, Human samples. Cited in 103 publications.
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Phosphatidylinositol 3-kinase p110 beta (PI3 kinase p110β) also known as PI3Kβ is an enzyme that belongs to the class I PI3-kinases. It functions as a catalytic subunit in the PI3K complex. The PI3 kinase p110β has a molecular mass of approximately 122 kDa. This protein is expressed in various tissues with notable presence in heart and skeletal muscles. The enzyme is responsible for phosphorylating PIP2 to generate PIP3 an essential step in signaling pathways that regulate cell growth and survival.
PI3 kinase p110β plays a role in the regulation of cellular processes such as proliferation migration and metabolism. It is a component of the PI3K complex comprised of regulatory and catalytic subunits which form functional homodimers or heterodimers. This complex is activated by various receptors including G-protein coupled receptors (GPCRs) and tyrosine kinase receptors. By converting PIP2 to PIP3 it aids in the recruitment and activation of downstream signaling proteins like AKT.
PI3 kinase p110β is integral in the PI3K/AKT signaling pathway and also contributes to the regulation of the mTOR pathway. These pathways are critical for controlling cellular responses to growth signals and maintaining homeostasis. Association with proteins like PTEN which negatively regulates the PI3K/AKT pathway highlights its importance in maintaining cellular balance. PI3 kinase p110β also interacts with other PI3 proteins like p110α showing the intricate network of signaling it participates in.
PI3 kinase p110β has been implicated in cancer and cardiovascular diseases. Its overactivation leads to unchecked cellular proliferation contributing significantly to oncogenesis. Alterations in the PI3K/AKT/mTOR pathway are common in breast cancer highlighting its interaction with proteins such as ERBB2. In cardiovascular disorders PI3 kinase p110β influences heart development and function where it can impact the action of related proteins like PI3 kinase p110α. The study of PI3 kinase p110β in these diseases offers potential for targeted therapies and improved understanding of its pathological roles.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-PI3 Kinase p110 beta antibody [EPR5515(2)] (ab151549) at 1/1000 dilution
Lane 1: Rat Brain Lysate at 10 µg
Lane 2: Mouse Brain Lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), HRP- conjugated at 1/1000 dilution
Predicted band size: 123 kDa
ab151549 staining PI3 Kinase p110 in the HeLa cell line by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% Paraformaldehyde permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody (1/150).Goat Anti-Rabbit IgG H&L (Alexa Fluor® 555) preadsorbed ab150082 an Alexa Fluor®555-conjugated Goat anti-rabbit IgG(1/500) was used as the secondary antibody. Nuclei were counterstained with DAPI.
All lanes: Western blot - Anti-PI3 Kinase p110 beta antibody [EPR5515(2)] (ab151549) at 1/5000 dilution
All lanes: K562 Cell Lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), HRP- conjugated at 1/1000 dilution
Predicted band size: 123 kDa
Observed band size: 110 kDa
All lanes: Western blot - Anti-PI3 Kinase p110 beta antibody [EPR5515(2)] (ab151549) at 1/1000 dilution
Lane 1: 293 Cell Lysate at 10 µg
Lane 2: Jurkat Cell Lysate at 10 µg
Lane 3: MCF-7 Cell Lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), HRP- conjugated at 1/1000 dilution
Predicted band size: 123 kDa
Observed band size: 110 kDa
All lanes: Western blot - Anti-PI3 Kinase p110 beta antibody [EPR5515(2)] (ab151549) at 1/1000 dilution
Lane 1: MCF7 cell lysate at 10 µg
Lane 2: Jurkat cell lysate at 10 µg
Lane 3: K562 cell lysate at 10 µg
Lane 4: 293T cell lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 123 kDa
Immunofluorescent analysis of 293 cells labelling PI3 Kinase p110 beta with unpurified ab151549 at 1/10 dilution.
Flow cytometry analysis of 80% methanol-fixed 0.1% Tween-20-permeabilized MCF7 cells stained with ab151549 at 1/50 dilution (red) and secondary Goat anti-Rabbit IgG (Alexa Fluor® 647, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 647) preadsorbed ab150083) at 1/5000 dilution. The isotype control was Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) / Black and the control used was cells without incubation with primary antibody and secondary antibody / Blue.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab151549).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com